Profile data is unavailable for this security.
About the company
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; Transient Receptor Potential Melastatin 3 (TRPM3) antagonism for migraine and neuropathic pain; Tyrosine Kinase 2/Janus Kinase 1 (TYK2/JAK1) inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; and antibody recruiting, bispecific molecules and antibody drug conjugates (ADCs) for cancer. The Troriluzole is a new chemical entity (NCE) and tripeptide prodrug of the active metabolite, riluzole.
- Revenue in USD (TTM)0.00
- Net income in USD-408.17m
- Incorporated--
- Employees239.00
- LocationBiohaven Ltd215 Church StreetNEW HAVEN 06510United StatesUSA
- Phone+1 (203) 404-0410
- Websitehttps://www.biohaven.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xenon Pharmaceuticals Inc | 0.00 | -182.39m | 3.02bn | 251.00 | -- | 3.26 | -- | -- | -2.73 | -2.73 | 0.00 | 12.31 | 0.00 | -- | -- | 0.00 | -21.22 | -20.71 | -21.86 | -21.81 | -- | -- | -- | -683.58 | -- | -- | 0.00 | -- | -100.00 | -- | -45.99 | -- | 61.77 | -- |
| 10X Genomics Inc | 618.73m | -255.10m | 3.21bn | 1.26k | -- | 4.32 | -- | 5.18 | -2.18 | -2.18 | 5.28 | 6.22 | 0.6206 | 2.70 | 5.65 | 491,443.20 | -25.59 | -25.52 | -29.39 | -29.05 | 66.15 | 75.88 | -41.23 | -48.53 | 4.11 | -- | 0.00 | -- | 19.81 | 33.43 | -53.67 | -- | 49.15 | -- |
| Iovance Biotherapeutics Inc | 1.19m | -444.04m | 3.22bn | 557.00 | -- | 5.06 | -- | 2,710.85 | -1.89 | -1.89 | 0.0051 | 2.28 | 0.0017 | -- | -- | 2,134.65 | -61.49 | -51.47 | -71.47 | -57.56 | -804.54 | -- | -37,345.42 | -137,873.80 | 2.70 | -- | 0.0017 | -- | -- | -- | -12.16 | -- | 79.44 | -- |
| Fortrea Holdings Inc | 3.11bn | -3.40m | 3.25bn | 18.00k | -- | 1.86 | 34.93 | 1.04 | -0.0379 | -0.0379 | 35.03 | 19.58 | -- | -- | -- | 172,722.20 | -- | -- | -- | -- | 16.74 | -- | -0.1094 | -- | -- | 1.27 | 0.478 | -- | 0.4167 | -- | -101.76 | -- | -- | -- |
| SpringWorks Therapeutics Inc | 5.45m | -325.10m | 3.27bn | 305.00 | -- | 5.19 | -- | 600.96 | -5.14 | -5.14 | 0.0862 | 8.52 | 0.008 | -- | -- | 17,859.02 | -47.95 | -36.97 | -53.00 | -39.49 | 92.25 | -- | -5,968.50 | -2,176.46 | 6.37 | -- | 0.00 | -- | -- | -- | -17.19 | -- | 90.68 | -- |
| Crinetics Pharmaceuticals Inc | 4.01m | -214.53m | 3.30bn | 290.00 | -- | 5.35 | -- | 821.24 | -3.70 | -3.70 | 0.0691 | 7.91 | 0.0081 | -- | 0.7048 | 13,837.93 | -42.39 | -42.53 | -45.71 | -45.36 | -- | -- | -5,216.32 | -5,446.39 | -- | -- | 0.00 | -- | -15.28 | 10.57 | -30.88 | -- | 34.65 | -- |
| Axsome Therapeutics Inc | 270.60m | -239.24m | 3.39bn | 545.00 | -- | 17.73 | -- | 12.52 | -5.20 | -5.20 | 5.96 | 4.03 | 0.5885 | 2.68 | 4.08 | 496,513.80 | -52.02 | -64.55 | -69.92 | -82.23 | 90.37 | -- | -88.41 | -227.05 | 3.52 | -35.93 | 0.4825 | -- | 440.80 | -- | -27.84 | -- | 77.86 | -- |
| Biohaven Ltd | 0.00 | -408.17m | 3.40bn | 239.00 | -- | 7.30 | -- | -- | -5.67 | -5.67 | 0.00 | 5.28 | 0.00 | -- | -- | 0.00 | -69.48 | -- | -79.29 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 28.43 | -- | -- | -- |
| Immunitybio Inc | 622.00k | -583.20m | 3.44bn | 628.00 | -- | -- | -- | 5,536.81 | -1.13 | -1.13 | 0.0012 | -0.875 | 0.0014 | -- | 0.246 | 990.45 | -134.71 | -112.76 | -377.77 | -316.07 | -- | -- | -93,866.88 | -37,700.74 | -- | -2.08 | 3.32 | -- | 159.17 | 67.62 | -40.00 | -- | 18.48 | -- |
| Simply Good Foods Co | 1.27bn | 140.76m | 3.46bn | 271.00 | 24.86 | 2.10 | 21.38 | 2.73 | 1.39 | 1.39 | 12.53 | 16.48 | 0.5977 | 6.91 | 8.56 | 4,671,908.00 | 6.65 | 3.66 | 6.95 | 3.83 | 37.26 | 38.90 | 11.12 | 6.80 | 3.09 | 9.26 | 0.1261 | 0.00 | 6.33 | 23.56 | 23.03 | 13.65 | 47.09 | -- |
| Ultragenyx Pharmaceutical Inc | 434.25m | -606.64m | 3.61bn | 1.28k | -- | 13.11 | -- | 8.31 | -8.33 | -8.33 | 5.91 | 3.35 | 0.286 | 1.49 | 7.63 | 340,320.50 | -39.96 | -33.35 | -48.63 | -38.30 | 89.59 | 93.13 | -139.70 | -154.71 | 2.49 | -- | 0.00 | -- | 19.52 | 53.18 | 14.25 | -- | 62.91 | -- |
| Alvotech SA | 93.38m | -551.73m | 3.64bn | 999.00 | -- | -- | -- | 39.00 | -2.40 | -2.40 | 0.4109 | -3.49 | 0.105 | 2.20 | 1.39 | 93,475.48 | -62.04 | -- | -81.72 | -- | -72.26 | -- | -590.83 | -- | 0.4614 | -1.29 | 7.52 | -- | 9.84 | -- | -7.43 | -- | -- | -- |
| Insmed Inc | 305.21m | -749.57m | 3.70bn | 912.00 | -- | -- | -- | 12.13 | -5.35 | -5.35 | 2.17 | -2.24 | 0.2044 | 0.8562 | 8.61 | 334,657.90 | -50.20 | -40.96 | -58.32 | -46.88 | 78.52 | 77.99 | -245.59 | -212.92 | 3.75 | -17.21 | 1.39 | -- | 24.39 | 98.78 | -55.66 | -- | -2.15 | -- |
Data as of Apr 26 2024. Currency figures normalised to Biohaven Ltd's reporting currency: US Dollar USD
46.37%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| 1919 Investment Counsel LLCas of 31 Dec 2023 | 6.22m | 7.62% |
| Janus Henderson Investors US LLCas of 31 Dec 2023 | 5.70m | 6.98% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 5.08m | 6.22% |
| Suvretta Capital Management LLCas of 31 Dec 2023 | 4.57m | 5.60% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 3.87m | 4.74% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 3.05m | 3.74% |
| RP Management LLC (Investment Management)as of 31 Dec 2023 | 2.94m | 3.60% |
| Point72 Asset Management LPas of 31 Dec 2023 | 2.48m | 3.04% |
| Adage Capital Management LPas of 31 Dec 2023 | 2.02m | 2.47% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 1.93m | 2.36% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
